...
cstl-img

Castle Biosciences Inc, Common Stock

CSTL

NMQ

$28.87

-$0.25

(-0.86%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$825.65M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
138.6667
Volume info-icon
This is the total number of shares traded during the most recent trading day.
279.02K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.98
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$16.96 L
$35.84 H
$28.87

About Castle Biosciences Inc, Common Stock

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCSTLSectorS&P500
1-Week Return-7.44%-2.27%-0.57%
1-Month Return-9.21%-3.96%1.21%
3-Month Return-7.41%-9.7%7.57%
6-Month Return27.29%-3.37%11.45%
1-Year Return40.49%3.71%28.48%
3-Year Return-28.57%3.8%29.52%
5-Year Return-2.14%39.78%90.66%
10-Year Return34.91%106.91%203.75%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue51.87M62.65M94.08M137.04M219.79M[{"date":"2019-12-31","value":23.6,"profit":true},{"date":"2020-12-31","value":28.5,"profit":true},{"date":"2021-12-31","value":42.81,"profit":true},{"date":"2022-12-31","value":62.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue7.31M9.69M15.82M32.01M44.98M[{"date":"2019-12-31","value":16.25,"profit":true},{"date":"2020-12-31","value":21.53,"profit":true},{"date":"2021-12-31","value":35.17,"profit":true},{"date":"2022-12-31","value":71.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit44.55M52.96M78.26M105.03M174.81M[{"date":"2019-12-31","value":25.49,"profit":true},{"date":"2020-12-31","value":30.3,"profit":true},{"date":"2021-12-31","value":44.77,"profit":true},{"date":"2022-12-31","value":60.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin85.91%84.54%83.18%76.64%79.53%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.41,"profit":true},{"date":"2021-12-31","value":96.83,"profit":true},{"date":"2022-12-31","value":89.22,"profit":true},{"date":"2023-12-31","value":92.58,"profit":true}]
Operating Expenses37.23M59.51M118.34M196.17M242.78M[{"date":"2019-12-31","value":15.33,"profit":true},{"date":"2020-12-31","value":24.51,"profit":true},{"date":"2021-12-31","value":48.74,"profit":true},{"date":"2022-12-31","value":80.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income4.71M(6.54M)(40.08M)(91.14M)(67.98M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-138.98,"profit":false},{"date":"2021-12-31","value":-851.48,"profit":false},{"date":"2022-12-31","value":-1936.31,"profit":false},{"date":"2023-12-31","value":-1444.17,"profit":false}]
Total Non-Operating Income/Expense(3.62M)(5.92M)134.00K7.90M20.38M[{"date":"2019-12-31","value":-17.75,"profit":false},{"date":"2020-12-31","value":-29.05,"profit":false},{"date":"2021-12-31","value":0.66,"profit":true},{"date":"2022-12-31","value":38.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income5.35M(10.20M)(40.01M)(68.90M)(57.37M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-190.69,"profit":false},{"date":"2021-12-31","value":-748.03,"profit":false},{"date":"2022-12-31","value":-1288.17,"profit":false},{"date":"2023-12-31","value":-1072.44,"profit":false}]
Income Taxes72.00K84.00K(8.72M)(1.77M)101.00K[{"date":"2019-12-31","value":71.29,"profit":true},{"date":"2020-12-31","value":83.17,"profit":true},{"date":"2021-12-31","value":-8633.66,"profit":false},{"date":"2022-12-31","value":-1748.51,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes5.28M(10.28M)(31.29M)(67.14M)(57.47M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-194.88,"profit":false},{"date":"2021-12-31","value":-592.99,"profit":false},{"date":"2022-12-31","value":-1272.28,"profit":false},{"date":"2023-12-31","value":-1088.99,"profit":false}]
Income From Continuous Operations5.28M(10.28M)(31.29M)(67.14M)(75.50M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-194.88,"profit":false},{"date":"2021-12-31","value":-592.99,"profit":false},{"date":"2022-12-31","value":-1272.28,"profit":false},{"date":"2023-12-31","value":-1430.81,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income5.28M(10.28M)(31.29M)(67.14M)(57.47M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-194.88,"profit":false},{"date":"2021-12-31","value":-592.99,"profit":false},{"date":"2022-12-31","value":-1272.28,"profit":false},{"date":"2023-12-31","value":-1088.99,"profit":false}]
EPS (Diluted)(2.11)(0.56)(1.23)(2.58)(2.16)[{"date":"2019-12-31","value":-211,"profit":false},{"date":"2020-12-31","value":-56,"profit":false},{"date":"2021-12-31","value":-123,"profit":false},{"date":"2022-12-31","value":-258,"profit":false},{"date":"2023-12-31","value":-216,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CSTL
Cash Ratio 6.32
Current Ratio 7.78
Quick Ratio 7.64

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CSTL
ROA (LTM) -0.14%
ROE (LTM) 1.47%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CSTL
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CSTL
Trailing PE 137.48
Forward PE NM
P/S (TTM) 2.65
P/B 1.83
Price/FCF 49
EV/R 1.78
EV/Ebitda 22.15

FAQs

What is Castle Biosciences Inc share price today?

Castle Biosciences Inc (CSTL) share price today is $28.87

Can Indians buy Castle Biosciences Inc shares?

Yes, Indians can buy shares of Castle Biosciences Inc (CSTL) on Vested. To buy Castle Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CSTL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Castle Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Castle Biosciences Inc (CSTL) via the Vested app. You can start investing in Castle Biosciences Inc (CSTL) with a minimum investment of $1.

How to invest in Castle Biosciences Inc shares from India?

You can invest in shares of Castle Biosciences Inc (CSTL) via Vested in three simple steps:

  • Click on Sign Up or Invest in CSTL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Castle Biosciences Inc shares
What is Castle Biosciences Inc 52-week high and low stock price?

The 52-week high price of Castle Biosciences Inc (CSTL) is $35.84. The 52-week low price of Castle Biosciences Inc (CSTL) is $16.96.

What is Castle Biosciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Castle Biosciences Inc (CSTL) is 138.6667

What is Castle Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Castle Biosciences Inc (CSTL) is 1.83

What is Castle Biosciences Inc dividend yield?

The dividend yield of Castle Biosciences Inc (CSTL) is 0.00%

What is the Market Cap of Castle Biosciences Inc?

The market capitalization of Castle Biosciences Inc (CSTL) is $825.65M

What is Castle Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of Castle Biosciences Inc is CSTL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top